American Bio Medica Corporation (ABMC)

Market Cap	4.81K
Revenue (ttm)	331,000
Net Income (ttm)	3.63M
Shares Out	48.10M
EPS (ttm)	0.08
PE Ratio	0.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Open	0.0001
Previous Close	0.0001
Day's Range	n/a
52-Week Range	0.0001 - 0.0130
Beta	-0.12
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ABMC

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detec...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 24, 1997
• Employees: 24
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABMC

Financial Performance

In 2022, ABMC's revenue was $913,000, a decrease of -58.84% compared to the previous year's $2.22 million. Losses were -$1.41 million, 204.5% more than in 2021.